Primus In News
Blockbuster semaglutide set to go off patent, Indian pharma sees a multi-billion-dollar opportunity
11-08-2025
Vivek Tandon, Vice President, Primus Partners, shares his view on the opportunities for Indian pharma companies in the semaglutide market. He highlights that India, being the world’s largest supplier of generics with over 20 percent share, is well positioned to disrupt the global market with high-quality semaglutide generics once the drug goes off patent. He added that Indian pharmaceutical majors have been preparing for this opportunity for several years.
Explore Related Insights
- Budget 2023: 95% of penalty amount on MSMEs for failure to execute contracts during Covid to be returned
- Primus Partners sets up a Solutions Excellence Centre for leveraging Digital Public Infrastructure
- Defence Procurements: Indian Air Force
- Xavier Institute of Management, Bhubaneswar to host the annual conclaves from November 7th to November 22th, 2020